| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3820 |
| Trial ID | NCT06334991 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 t-haNK |
| Co-treatment | Rituximab |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | Open-Label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With Rituximab in Subjects With Selected CD19+ and CD20+ Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |
| Year | 2024 |
| Country | United States |
| Company sponsor | ImmunityBio, Inc. |
| Other ID(s) | QUILT-106 |
| Cohort 1 | |||||||
|
|||||||